NEW YORK – Evercore ISI downgraded shares of Twist Bioscience to an In-Line rating on Monday, setting a price target of $140.
"We don't debate that Twist is one of the more exciting companies under coverage," Evercore analyst Vijay Kumar and colleagues wrote in a research note, adding that the firm's fiscal year 2021 revenue guidance is conservative. "That said, key new growth verticals will take time to develop," they wrote, namely the firm's biopharma and DNA-based data storage businesses.
The time it would take to reach a Phase III clinical trial and the uncertainties remaining with DNA-based data storage "could take time to translate into meaningful revenue opportunity," according to the analysts.
Over the course of 2020, shares of Twist rose approximately 700 percent, closing at $141.29 on Dec. 31, 2020.
In afternoon trading on the Nasdaq, shares of Twist were down 5 percent at $134.21.